Altimmune, Inc., a clinical-stage biopharmaceutical company, announced it will be added to the Nasdaq Biotechnology Index effective December 23, 2024. This milestone marks a significant achievement ...
GAITHERSBURG, Md. - Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company trading at $7.90 per share, will be included in the Nasdaq Biotechnology Index (NASDAQ:NBI) starting Monday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results